Minneapolis-based FastWave develops laser-based intravascular lithotripsy (IVL) technology for treating calcific artery disease. Its platform offers durable and fast energy delivery with enhanced sonic output to navigate complex arterial anatomy through a high-performing catheter.

FastWave’s IVL technology is currently being used in a first-in-human study kicked off earlier this year.

IVL is a fast-growing space, with Johnson & Johnson’s recent $13.3 billion acquisition of Shockwave Medical highlighting that. Learn more about FastWave Medical and IVL at DeviceTalks Boston May 1-2.

The latest patent for FastWave covers the company’s novel next-generation laser-IVL technology.

In a news release, Dr. William Nicholson, a physician advisor for FastWave, said the company’s novel approach “has enormous potential to leapfrog today’s IVL technology with durable, fast, and consistent laser energy.”